MWM
IBRX icon

MOR Wealth Management’s ImmunityBio IBRX Stock Holding History

MOR Wealth Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.65M Buy
302,447
+19,200
+7% +$145K 1.05% 20
2026
Q1 		$2.17M Buy
283,247
+33,982
+14% +$233K 1% 20
2025
Q4 		$494K Buy
+249,265
New +$565K 0.23% 58

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MOR Wealth Management's IBRX Position: Q2 2026 in Review

MOR Wealth Management increased its ImmunityBio (IBRX) stake by 6.8% in Q2 2026, buying an estimated $145K and bringing the position to 302,447 shares worth $2.65M. The position accounts for 1.05% of the portfolio, ranked #20.

MOR Wealth Management first reported a position in IBRX in Q4 2025 and has held it in 3 quarters since. 402 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • MOR Wealth Management held 302,447 shares of ImmunityBio worth $2.65M as of Q2 2026.
  • MOR Wealth Management bought 19,200 ImmunityBio shares in Q2 2026, an estimated $145K.
  • ImmunityBio made up 1.05% of MOR Wealth Management's portfolio in Q2 2026, its #20 holding.
  • MOR Wealth Management first reported a position in ImmunityBio in Q4 2025 and has held it in 3 quarters since.
  • 402 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on MOR Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.